drugset / Trial / NCT05745857
Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas
Non-randomizedFactorialOpen-labelPrevention
Summary
Previous studies have confirmed the great potential of quantitative fluorescence molecular endoscopy (qFME) when looking at additional lesion detection initially missed by high-definition white light endoscopy (HD-WLE) for surveillance of Barrett's esophagus.
Timeline
- Start
- 2023-09-15
- Primary completion
- 2026-05
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Oral |
| Subject | Cetuximab | Monoclonal antibody | — | Oral |